Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 88

Results For "IMI"

4535 News Found

Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
News | August 05, 2025

Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr

The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore


Sandoz to acquire Just–Evotec Biologics facility for $300 million
News | August 03, 2025

Sandoz to acquire Just–Evotec Biologics facility for $300 million

The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes


NIH develops AI agent to improve accuracy of gene set analysis
Digitisation | August 03, 2025

NIH develops AI agent to improve accuracy of gene set analysis

The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases


GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
News | August 03, 2025

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results


Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr
News | August 02, 2025

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter


USPTO issues final rejection of Rampart IC's radiation shield patent claims
News | August 02, 2025

USPTO issues final rejection of Rampart IC's radiation shield patent claims

The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent


Fermenta receives CEP by EDQM for Vitadee 100 SD
Biotech | August 01, 2025

Fermenta receives CEP by EDQM for Vitadee 100 SD

Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3


Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr
News | August 01, 2025

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025